Gwyndod Project Debate
Full Debate: Read Full DebateLord Patel
Main Page: Lord Patel (Crossbench - Life peer)Department Debates - View all Lord Patel's debates with the Department for Energy Security & Net Zero
(1 day, 18 hours ago)
Lords Chamber
Baroness Curran (Lab)
Of course infrastructure is vital, and I recognise the point the noble Baroness makes about Wales becoming a world leader and her commitment to Wales. This Government support the development of infrastructure very strongly, as has been evidenced on many occasions. The Government will work in partnership with the Welsh Government to deliver better transport in north Wales. This was demonstrated by Transport for Wales increasing the number of trains on the north Wales coastline by about half in May. In its planning for the delivery of the Gwyndod project, Great British Energy-Nuclear will consider the infrastructure required.
My Lords, we have in the NHS a network of cyclotrons, which produce loaded medical isotopes. What we do not have is reactor-based production of isotopes, so we import 80% to 90% of those isotopes from abroad, with supply chains often precarious. This means that our patients, particularly cancer patients, have delays in getting their treatment. The Welsh Government produced a good business plan for reactor-based production of isotopes in Wales, at a cost of £400 million and lasting 70 years. If Wales is not an ideal place, maybe the Government will consider Scotland—but when are we going to have such reactor-based production?
Baroness Curran (Lab)
The noble Lord has raised a very important point. I would always support the performance of devolved Governments in the UK, and I note the point he makes. I understand there have been discussions on the Project ARTHUR proposal with the Department of Health and Social Care, though there has not been any formal commitment to a specific project. I assure the noble Lord that the Government are committed to ensuring resilient medical radioisotope supplies and making use of diverse international supply chains, alongside greater UK manufacturing capability. Wider funding, including through the £520 million life sciences innovative manufacturing fund, has been made available to support UK manufacturing. However, I note the point he has made about Scotland and his other points, and I will ensure they are communicated to the relevant departments, because if it is raised in Parliament in this manner, it matters to departments and they should pay attention to it.